MedTrace Logo

Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria

NCT07378527 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 344

Last updated 2026-04-21

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy and safety of ICP-332 in moderate to severe chronic spontaneous urticaria subjects inadequately controlled by second generation H1-antihistamines

Conditions

  • Chronic Spontaneous Urticaria (CSU)

Interventions

DRUG

ICP-332 Tablets

ICP-332 will be administered as tablet for 12 weeks

DRUG

ICP-332 placebo Tablets

ICP-332 placebo will be administered as tablet for 12 weeks

DRUG

ICP-332 Tablets

ICP-332 will be administered as tablet for 24 weeks

Sponsors & Collaborators

  • Beijing InnoCare Pharma Tech Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-13
Primary Completion
2028-09-30
Completion
2028-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07378527 on ClinicalTrials.gov